---
title: "The FDA’s Manufacturing Pre-Check Pilot Program: A Submission Checklist for Biologics Sponsors"
description: Learn how FDA's Manufacturing Pre-Check Pilot Program enhances manufacturing readiness for biologics sponsors, promoting proactive regulatory engagement.
---

[Insights & Intel: The Bracken Blog ](https://www.thebrackengroup.com/blog)

# [The FDA’s Manufacturing Pre-Check Pilot Program: A Submission Checklist for Biologics Sponsors](https://www.thebrackengroup.com/blog/the-fdas-manufacturing-pre-check-pilot-program-a-submission-checklist-for-biologics-sponsors)

 Written by [Bracken](https://www.thebrackengroup.com/blog/author/bracken) | May 7, 2026 5:12:21 PM

The FDA’s Manufacturing Pre-Check Pilot Program reflects a clear shift in regulatory strategy: earlier, more proactive engagement around manufacturing readiness. As supply chain resilience and domestic production capacity become national priorities, the agency is placing greater emphasis on ensuring facilities are inspection-ready well before formal submission milestones.

For biologics sponsors, this is not just another regulatory initiative. It’s an early signal of how FDA expects companies to think about manufacturing: structured, transparent, and ready for scrutiny well in advance of licensure.

###### What Is the FDA Manufacturing Pre-Check Pilot Program?

The Pre-Check Pilot Program is designed to give sponsors early feedback on the readiness of their manufacturing facilities, particularly those based in the United States. Introduced as a new pilot initiative, the program is part of FDA’s broader effort to enable earlier, more structured insight into manufacturing readiness—before it becomes a regulatory bottleneck. Rather than waiting for pre-approval inspections tied to a BLA or similar filing, companies can engage the FDA in advance to evaluate their operational and quality preparedness.

The program is intended for:

The core benefit is straightforward: early identification of gaps that could otherwise delay approval or trigger inspection findings later in the process.

###### **Program Status Update**

 *The initial application window for the pilot program has closed following strong industry interest. The FDA is currently reviewing submissions based on published eligibility and selection criteria. Finalists were expected to be notified by April 1, 2026, with final participant selections anticipated by June 30, 2026. Due to the volume of submissions, the FDA is not providing interim status updates. Future iterations or expansions of the program may be announced.* 

**Why FDA Introduced the Pre-Check Program**

The program is part of a broader effort to modernize regulatory oversight and reduce friction in the development-to-commercialization pathway. Specifically, it aims to:

In practice, this reflects a shift away from reactive compliance toward proactive risk management.

###### **Submission Checklist: How to Prepare for the Pre-Check Program**

Even with the initial cohort closed, this checklist remains relevant. Future iterations of the program or similar early-engagement pathways are likely, and the underlying expectations will not change.

**1. Facility Readiness Documentation**

Provide a detailed description of the manufacturing site, including:

Clarity here sets the foundation for all downstream evaluation.

**2. CMC (Chemistry, Manufacturing, and Controls) Alignment**

Ensure that your manufacturing strategy is consistent with regulatory expectations:

Misalignment between CMC documentation and actual operations is a common source of regulatory friction.

**3. Quality Systems & Compliance Framework**

Demonstrate that your quality infrastructure is mature and functional:

This is an area where superficial documentation is quickly exposed, and depth matters.

**4. Manufacturing Process Maturity**

Be explicit about where your process stands:

Submitting too early, before process maturity is established, weakens the value of the program.

**5. Inspection Readiness Indicators**

Show evidence that the facility can withstand regulatory scrutiny:

The FDA is not expecting perfection, but they will expect awareness and control of risks.

**6. Regulatory Engagement History**

Provide context on prior interactions:

This helps the agency assess continuity and consistency across your regulatory strategy.

**7. Strategic Rationale for Participation**

Clearly articulate why you are applying:

A vague rationale signals a lack of internal alignment.

 

What to Expect After Submission

While specifics may evolve as the pilot progresses, sponsors should expect structured, advisory feedback rather than formal regulatory determinations.

Potential outcomes include:

Timelines for the initial cohort are currently tied to the FDA’s ongoing review process, with final selections expected by mid-2026.

###### Strategic Implications for Biologics Companies

The Pre-Check Program offers a meaningful advantage for companies willing to invest in early readiness. It enables:

- - Greater visibility into regulatory risk
    - More predictable timelines leading into approval
    - Stronger positioning for facilities supporting U.S.-based manufacturing

 However, it is not a shortcut. Participation requires substantial upfront coordination across CMC, quality, and regulatory teams. Organizations that treat this as a box-checking exercise will see limited value

 

###### Common Pitfalls to Avoid

Several risks can undermine the effectiveness of participation:

The program rewards preparedness, not intent.

###### How to Decide if the Program is Right for You

The Pre-Check Program is best suited for:

It is less appropriate for:

For now, companies should focus on readiness, both for potential future cohorts and for broader FDA engagement expectations. 

Conclusion 

If you’re evaluating how this program or its future iterations fits into your development strategy, the next step is a candid readiness assessment. Are you positioned to benefit from early FDA feedback, or would it expose gaps you’re not ready to address? [Contact Bracken’s regulatory and CMC strategy experts to learn how we can support you](https://www.thebrackengroup.com/contact). 

  

[View full post](https://www.thebrackengroup.com/blog/the-fdas-manufacturing-pre-check-pilot-program-a-submission-checklist-for-biologics-sponsors)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Bracken"
  },
  "dateModified" : "2026-05-07T17:12:21.553Z",
  "datePublished" : "2026-05-07T17:12:21Z",
  "headline" : "The FDA’s Manufacturing Pre-Check Pilot Program: A Submission Checklist for Biologics Sponsors",
  "image" : {
    "@type" : "ImageObject",
    "height" : 512,
    "url" : "https://4628766.fs1.hubspotusercontent-na1.net/hubfs/4628766/chub_backup/Untitled%20design%20%2886%29.png",
    "width" : 1024
  },
  "mainEntityOfPage" : "https://www.thebrackengroup.com/blog/the-fdas-manufacturing-pre-check-pilot-program-a-submission-checklist-for-biologics-sponsors",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Blog"
  }
}
```